array(1) {
  [0]=>
  object(Apache_Solr_Document)#24 (3) {
    ["_documentBoost":protected]=>
    bool(false)
    ["_fields":protected]=>
    array(6) {
      ["content_id"]=>
      array(1) {
        [0]=>
        string(15) "DIRECTORY_10449"
      }
      ["content_title"]=>
      array(1) {
        [0]=>
        string(21) "MASSIMILIANO AGOSTINI"
      }
      ["description"]=>
      array(1) {
        [0]=>
        string(23172) "<document><p>
	CURRICULUM VITAE ET STUDIORUM</p>
<p>
	Prof MASSIMILIANO AGOSTINI</p>
<p>
	<span class="totem_bold">DATI PERSONALI</span></p>
<p>
	Nome&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AGOSTINI Massimiliano</p>
<p>
	Data di Nascita&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20 Gennaio 1972</p>
<p>
	Luogo di nascita&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Terni, Italia</p>
<p>
	Cittadinanza&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Italiana</p>
<p>
	Indirizzo Lavoro&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Universita' di Roma, Tor Vergata, Dip. Medicina Sperimental via Montpellier, 1 00133 Roma</p>
<p>
	&nbsp;</p>
<p>
	ORCID&nbsp;&nbsp;identifier&nbsp;0000-0003-3124-2072 &nbsp;</p>
<p>
	Public record&nbsp;&nbsp;&nbsp;&nbsp;http://orcid.org/0000-0003-3124-2072</p>
<p>
	Scopus&nbsp;&nbsp;Author ID: 7005322176&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p>
	Researcher ID:&nbsp;G-9579-2014&nbsp;http://www.researcherid.com/rid/G-9579-2014</p>
<p>
	&nbsp;</p>
<p>
	<span class="totem_bold">POSITIONE ATTUALE:</span></p>
<p>
	Professore Associato, Biologia Molecolare, Universita' di Tor Vergata</p>
<p>
	<span class="totem_bold">EDUCAZIONE</span></p>
<p>
	1991&nbsp;Diploma:&nbsp;Istituto Tecnico Industriale (Perito Chimico), Terni</p>
<p>
	1997&nbsp;Laurea:&nbsp;Chimica e Tecnologie Farmaceutiche.&nbsp;</p>
<p>
	1998&nbsp;Abilitazione alla professione di Farmacista</p>
<p>
	2006&nbsp;Dottorato di Ricerca in Farmacologia Clinica e Sperimentale</p>
<p>
	&nbsp;</p>
<p>
	<span class="totem_bold">ESPERIENZE PROFESSIONALI</span></p>
<p>
	1997-1999&nbsp;Studente interno presso Sezione di Farmacologia, Facolt&agrave; di Medicina Universit&agrave; di Perugia</p>
<p>
	1999-2001&nbsp;Borsa di Studio presso&nbsp;Sezione di Farmacologia, Facolt&agrave; di Medicina Universit&agrave; di Perugia</p>
<p>
	2005-2006&nbsp;Assegno di ricerca presso Sezione di Farmacologia, Facolt&agrave; di Medicina Universit&agrave; di Perugia</p>
<p>
	2006-2007&nbsp;Assegno di ricerca presso Sezione di Farmacologia, Facolt&agrave; di Medicina&nbsp;Universit&agrave; di Perugia</p>
<p>
	2007-2011&nbsp;Career Development Fellow, MRC Toxicology Unit, UK</p>
<p>
	2011-2014&nbsp;Senior Investigator, MRC Toxicology Unit, UK&nbsp;</p>
<p>
	2014&nbsp;Visiting Scientist, presso The Campbell Family Institute for Breast Cancer Research, Toronto, Canada</p>
<p>
	2014-Presente&nbsp;Professore Associato, Biologia Molecolare, Universita' di Tor Vergata, Dip. Medicina Sperimentale, Roma</p>
<p>
	2015-2019&nbsp;Visiting Scientist, MRC Toxicology Unit, Cambridge University, UK.</p>
<p>
	&nbsp;</p>
<p>
	<span class="totem_bold">SOCIETA&rsquo; SCIENTIFICHE&nbsp;</span></p>
<p>
	2002&nbsp;Societ&agrave; Italiana di farmacologia</p>
<p>
	&nbsp;</p>
<p>
	<span class="totem_bold">RICONOSCIMENTI</span></p>
<p>
	2005&nbsp;Migliore presentazione al XXXII National Congress of the Italian Pharmacological&nbsp;Society</p>
<p>
	<span class="totem_bold">ATTIVITA&rsquo; DIDATTICA</span></p>
<p>
	2015-&nbsp;ad oggi&nbsp;Collegio dei docenti Dottorato in Biochimica e Biologia Molecolare</p>
<p>
	2015-&nbsp;ad oggi&nbsp;Insegnamento&nbsp;Metabolomica e Trascrittomica&nbsp;Master II livello, Nutrizione Personalizzata: Basi molecolari e genetiche,&nbsp;Universita' di Tor Vergata, Italia</p>
<p>
	2016-&nbsp;ad oggi&nbsp;Insegnamento&nbsp;Metabolismo e Tumori&nbsp;Master I livello, Nutrizione e Cosmesi,&nbsp;Universita' di Tor Vergata</p>
<p>
	2016-2020&nbsp;Insegnamento&nbsp;Molecular biology e Biochemistry&nbsp;Course of Medicine and Surgery,&nbsp;Universita' di Tor Vergata</p>
<p>
	2017-&nbsp;ad oggi&nbsp;Insegnamento&nbsp;Biologia Molecolare&nbsp;Scuola di Specializzazione in Malattie Infettive, Universita' di Tor Vergata</p>
<p>
	2018-&nbsp;ad oggi&nbsp;Insegnamento&nbsp;Biologia Molecolare&nbsp;Scuola di Specializzazione in Microbiologia e Virologia. Universita' di Tor Vergata</p>
<p>
	2018-&nbsp;ad oggi&nbsp;Insegnamento&nbsp;Biologia Molecolare&nbsp;Scuola di Specializzazione in Endocrinologia e Malattie del Metabolismo Universita' di Tor Vergata</p>
<p>
	2017&nbsp;Corso di Formazione in &ldquo;Tutela della salute pubblica&rdquo;.</p>
<p>
	2018&nbsp;Corso di Formazione in &ldquo;Tutela della salute pubblica&rdquo;.</p>
<p>
	2017--2020&nbsp;Insegnamento&nbsp;Biologia Molecolare&nbsp;Laura Magistrale in Medicina e Chirurgia,&nbsp;Universita' di Tor Vergata</p>
<p>
	2020&nbsp;Insegnamento&nbsp;Biochemistry&nbsp;Corso di Laurea Magistrale a Ciclo Unico in Farmacia</p>
<p>
	2020&nbsp;Insegnamento&nbsp;Molecular biology&nbsp;Course of Medicine and Surgery,&nbsp;Universita' di Tor Vergata</p>
<p>
	2021-2022&nbsp;&nbsp;&nbsp;Scienze della nutrizione umana (Metabolomica)</p>
<p>
	2023-&nbsp;ad oggi&nbsp;Scienze della nutrizione umana (Nutrition, inflammation and cancer)</p>
<p>
	2023-&nbsp;ad oggi&nbsp;Biochemistry and Molecular Biology&nbsp;Scuola di Specializzazione in malattie dell&rsquo;apparato Cardiovascolare&nbsp;&nbsp;&nbsp;</p>
<p>
	2024-Present&nbsp;Molecular Biology&nbsp;Scuola di Specializzazione in Anatomia Patologica</p>
<p>
	&nbsp;</p>
<p>
	<span class="totem_bold">ATTIVITA&rsquo; EDITORIALE</span></p>
<p>
	2014-2019&nbsp;Editorial board of&nbsp;Molecular &amp; Cellular Oncology</p>
<p>
	2011-2023&nbsp;Receiving Editor&nbsp;Cell Death &amp; Disease</p>
<p>
	2011-ad oggi&nbsp;Editorial board as Review Editor of&nbsp;Frontiers in Oncology&rsquo;s speciality section&nbsp;Frontiers in Cancer Molecular Targets and Therapeutics</p>
<p>
	2022-&nbsp;ad oggi&nbsp;Editorial Board of&nbsp;Cancers</p>
<p>
	2023- ad oggi&nbsp;Deputy Editor&nbsp;Cell Death &amp; Disease</p>
<p>
	Ad hoc Referee:</p>
<p>
	Cell Death &amp; Disease, Cell Death and Differentiation, Frontiers in Cancer, Molecular and Cellular Oncology, Molecular Neurobiology, Oncogene, Oncotarget, Cell Cycle, FEBS Journal, Scientific Reports, Journal of Cellular Biochemestry, Molecular Oncology, FASEB Journal,&nbsp;Journal of Human Genetics, Biology Direct</p>
<p>
	&nbsp;</p>
<p>
	<span class="totem_bold">ATTIVITA&rsquo; DI RICERCA</span></p>
<p>
	MA &egrave; principalmente interessato nella caratterizzazione di topi transgenici con alterazioni genetiche della famiglia di p53 e dei target molecolari al fine di studiare la loro funzione nello sviluppo e nei tumori. In particolare, MA studia il ruolo del fattore di trascrizione ZNF750, la cui espressione e regolata da p63, nello sviluppo dei tumori usando approcci sperimentali sia&nbsp;in vitro&nbsp;che&nbsp;in vivo&nbsp;combinati con studi di biologia sistemica (trascrittomica, proteomica, metabolomica). Attualmente le principali linee di ricerca sono:</p>
<p>
	1) Studiare&nbsp;in vivo&nbsp;le funzioni delle specifiche isoforme della famiglia di p53</p>
<p>
	2) Il metabolismo dei lipidi come potenziale target per la cura dei tumori</p>
<p>
	3) Identificare in vivo le funzioni di ZNF750 nello sviluppo, nella fisiologia e nella tumorigenesi usando animali geneticamente modificati.&nbsp;</p>
<p>
	&nbsp;</p>
<p>
	<span class="totem_bold">PUBBLICAZIONI</span></p>
<p>
	Scientific Papers&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;86 (First Author: 20; Corresponding Author: 14)</p>
<p>
	Citations&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7886 (Scholar)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5285 (ISI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5694 (Scopus)</p>
<p>
	h-Index&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;46 (Scholar)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;38 (ISI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;40 (Scopus)</p>
<p>
	&nbsp;</p>
<p>
	<span>Most representative publication&nbsp;</span></p>
<p>
	1)&nbsp;&nbsp;&nbsp;&nbsp;Zhu M, et al&nbsp;Agostini M&nbsp;Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype&nbsp;Discov Oncol.&nbsp;2024 Jan 16;15(1):10. &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</p>
<p>
	2)&nbsp;&nbsp;&nbsp;&nbsp;Peng F, et al&nbsp;Alleviating hypoxia to improve cancer immunotherapy&nbsp;Oncogene&nbsp;2023 Dec;42(49):3591-3604</p>
<p>
	3)&nbsp;&nbsp;&nbsp;&nbsp;Butera A*,&nbsp;Agostini M*,&nbsp;et al ZFP750 affects the cutaneous barrier through regulating lipid metabolism&nbsp;Science Advances&nbsp;2023 Apr 28;9(17).&nbsp;(*) Co-First Author</p>
<p>
	4)&nbsp;&nbsp;&nbsp;&nbsp;Vitale I, et al. Apoptotic cell death in disease&mdash;Current understanding of the NCCD 2023&nbsp;Cell Death Differ&nbsp;2023 May;30(5):1097-1154</p>
<p>
	5)&nbsp;&nbsp;&nbsp;&nbsp;Agostini M*, et al&nbsp;Targeting lipid metabolism in cancer: neuroblastoma&nbsp;Cancer Metastasis&nbsp;Rev&nbsp;2022 Jun 10. doi: 10.1007/s10555-022-10040-8&nbsp;(*) Corresponding Author</p>
<p>
	6)&nbsp;&nbsp;&nbsp;&nbsp;Rugolo F, et al and&nbsp;Agostini M&nbsp;The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome&nbsp;Oncogene&nbsp;2021 Sep;40(38):5741-5751</p>
<p>
	7)&nbsp;&nbsp;&nbsp;&nbsp;Velletri T et al. Loss of p53 in mesenchymal stem cells promotes alteration of bone remodelling through negative regulation of osteoprotegerin.&nbsp;Cell Death Differ&nbsp;2020 Online ahead of print.</p>
<p>
	8)&nbsp;&nbsp;&nbsp;&nbsp;Amelio I et al&nbsp;The p73 C-terminus directs hippocampal development&nbsp;Proc Natl Acad Sci U S A2020&nbsp;117&nbsp;(27)&nbsp;15694-15701</p>
<p>
	9)&nbsp;&nbsp;&nbsp;&nbsp;Cassandri M et al.&nbsp;Agostini&nbsp;M&nbsp;and Melino G&nbsp;ZNF750 represses breast cancer invasion via epigenetic control of prometastatic genes&nbsp;Oncogene&nbsp;2020&nbsp;39,&nbsp;4331&ndash;4343&nbsp;</p>
<p>
	10)&nbsp;Agostini M, et al&nbsp;p73 regulates primary cortical neurons metabolism: a global metabolic profile&nbsp;Mol Neurobiol.&nbsp;2017&nbsp;2017 May 6. doi: 10.1007/s12035-017-0517-3.</p>
<p>
	11)&nbsp;Agostini M, et al&nbsp;Metabolic reprogramming during neuronal differentiation&nbsp;Cell Death Differ&nbsp;2016 Sep 1;23(9):1502-14.</p>
<p>
	12)&nbsp;Viticchi&egrave; G, et al&nbsp;ΔNp63&nbsp;supports aerobic respiration through hexokinase II&nbsp;Proc Natl Acad Sci USA. 2015 Sep 15;112(37):11577-82.&nbsp;</p>
<p>
	13)&nbsp;Amelio I, et al. Serine and glycine metabolism in Cancer&nbsp;Trends Biochem&nbsp;Sci&nbsp;2014 Apr;39(4):191-198.</p>
<p>
	14)&nbsp;Inoue S, et al. TAp73 is required for spermatogenesis and the maintenance of male fertility.&nbsp;Proc Natl Acad Sci USA. 2014;111(5):1843-8.&nbsp;</p>
<p>
	15)&nbsp;Niklison-Chirou MV, et al. TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75NTR&nbsp;&nbsp;Proc Natl Acad Sci U S A&nbsp;2013;110 (47):18952-7.&nbsp;</p>
<p>
	16)&nbsp;Tucci P*,&nbsp;Agostini M*, et al.&nbsp;Loss of p63 and its miR-205 target results in enhanced cell migration and metastasis in prostate cancer.&nbsp;Proc Natl Acad Sci U S A.&nbsp;2012 109(38):15312-7.&nbsp;(*) Co-First Author&nbsp;</p>
<p>
	17)&nbsp;He Z, et al.&nbsp;p73&nbsp;regulates autophagy and hepatocellular lipid metabolism through a transcriptional activation of the ATG5 gene.&nbsp;Cell Death Differ.&nbsp;2013 Oct;20(10):1415-24.</p>
<p>
	18)&nbsp;Amelio I, et al. p73 regulates serine biosynthesis in cancer.&nbsp;Oncogene.&nbsp;2013. doi: 10.1038/onc.2013.456.</p>
<p>
	19)&nbsp;Agostini M, et al. miR-34a regulates neurite outgrowth, spinal morphology and function.&nbsp;
	Proc Natl Acad Sci U S A.&nbsp;2011;108(52):21099-104.</p>
<p>
	20)&nbsp;Agostini M, et al.&nbsp;Neuronal differentiation by TAp73 is mediated by miR-34a regulation of synaptic protein targets.&nbsp;Proc Natl Acad Sci U S A. 2011;108(52):21093-8.</p></document><document><p>
	CURRICULUM VITAE ET STUDIORUM</p>
<p>
	Prof MASSIMILIANO AGOSTINI</p>
<p>
	<span class="totem_bold">PERSONAL DATA</span></p>
<p>
	Family name&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;AGOSTINI Massimiliano</p>
<p>
	Date of birth&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20 January 1972</p>
<p>
	Place of birth&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Terni, Italy</p>
<p>
	Citizenship&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Italian</p>
<p>
	Address&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dept. Experimental Medicine University of Rome &ldquo;Tor Vergata&rdquo;via Montpellier, 1 00133 Roma,&nbsp;</p>
<p>
	&nbsp;</p>
<p>
	ORCID&nbsp;&nbsp;identifier&nbsp;0000-0003-3124-2072&nbsp;&nbsp;&nbsp;</p>
<p>
	Public record&nbsp;&nbsp;&nbsp;&nbsp;http://orcid.org/0000-0003-3124-2072</p>
<p>
	Scopus&nbsp;&nbsp;Author ID: 7005322176&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p>
	Researcher ID:&nbsp;G-9579-2014&nbsp;http://www.researcherid.com/rid/G-9579-2014</p>
<p>
	&nbsp;</p>
<p>
	<span class="totem_bold">PRESENT POSITION</span></p>
<p>
	Associate Professor, Molecular Biology, University of Rome &ldquo;Tor Vergata&rdquo;, Italy</p>
<p>
	<span>EDUCATION</span></p>
<p>
	1997 Degree in&nbsp;Chemical and Pharmaceutical Technology</p>
<p>
	1998&nbsp;Pharmacist&nbsp;license,&nbsp;state of Italy</p>
<p>
	2006 PhD&nbsp;in Clinical and Experimental Pharmacology&nbsp;</p>
<p>
	<span class="totem_bold">CAREER HISTORY</span></p>
<p>
	1997-1999&nbsp;Visiting Fellow Section of Pharmacology, School of Medicine, University of Perugia</p>
<p>
	1999-2001&nbsp;Fellowship Section of Pharmacology, School of Medicine, University of Perugia</p>
<p>
	2005-2006&nbsp;Research Assistant Section of Pharmacology, School of Medicine, University of Perugia</p>
<p>
	2006-2007&nbsp;Research Assistant Section of Pharmacology, School of Medicine, University of Perugia</p>
<p>
	2007-2011&nbsp;Career Development Fellow, MRC Toxicology Unit, UK</p>
<p>
	2014-2014&nbsp;Visiting Scientist, at&nbsp;The Campbell Family Institute for Breast Cancer Research, Toronto, Canada</p>
<p>
	2011-2014&nbsp;Senior Investigator, MRC Toxicology Unit, UK</p>
<p>
	2014 to 2019&nbsp;Visiting Scientist, MRC Toxicology Unit, Cambridge University, UK</p>
<p>
	<span class="totem_bold">MEMBERSHIP</span></p>
<p>
	2002&nbsp;Italian Society of Pharmacology</p>
<p>
	<span class="totem_bold">TEACHING ACTIVITIES</span></p>
<p>
	2015-Present Metabolomics and Transcriptomics&nbsp;II level Master, Personalized Nutrition: Molecular and Genetic bases,University of Rome Tor Vergata</p>
<p>
	2016-Present&nbsp;Cancer Metabolism&nbsp;I level Master, Nutrition and Cosmesis,&nbsp;University of Rome Tor Vergata</p>
<p>
	2016-2020 Biochemistry and Molecular Biology&nbsp;International Medical School&nbsp;University of Rome Tor Vergata</p>
<p>
	2017-2020 Molecular Biology&nbsp;Medicine and Surgery,&nbsp;University of Rome Tor Vergata</p>
<p>
	2017-Present&nbsp;Molecular Biology&nbsp;Residency in Infection Disease University of Rome Tor Vergata, Italy</p>
<p>
	2019-Present&nbsp;Molecular Biology&nbsp;Residency in Endocrinology and Metabolic Diseases Virology University of Rome Tor Vergata</p>
<p>
	2019-Present&nbsp;Molecular Biology&nbsp;Residency in Microbiology and Virology University of Rome Tor Vergata</p>
<p>
	2020&nbsp;Biochemistry&nbsp;School of Pharmacy&nbsp;University of Rome Tor Vergata</p>
<p>
	2020 Molecular Biology&nbsp;International Medical School&nbsp;University of Rome Tor Vergata</p>
<p>
	2021-2022&nbsp;&nbsp;&nbsp;Scienze della nutrizione umana (Metabolomics)</p>
<p>
	2023-Present&nbsp;Scienze della nutrizione umana (Nutrition, inflammation and cancer)</p>
<p>
	2023-Present&nbsp;Biochemistry and Molecular Biology&nbsp;Residency in Cardiovascular Diseases&nbsp;&nbsp;&nbsp;</p>
<p>
	2024-Present&nbsp;Molecular Biology&nbsp;Residency in Pathological Anatomy</p>
<p>
	&nbsp;</p>
<p>
	<span class="totem_bold">EDITORIAL ACTIVITY</span></p>
<p>
	2014-2019&nbsp;Editorial board of&nbsp;Molecular &amp; Cellular Oncology</p>
<p>
	2011-2023&nbsp;Receiving Editor&nbsp;Cell Death &amp; Disease</p>
<p>
	2011-Present&nbsp;Editorial board as Review Editor of&nbsp;Frontiers in Oncology&rsquo;s speciality section&nbsp;Frontiers in Cancer Molecular Targets and Therapeutics</p>
<p>
	2022-Present&nbsp;Editorial Board of&nbsp;Cancers</p>
<p>
	2023-Present&nbsp;Deputy Editor&nbsp;Cell Death &amp; Disease</p>
<p>
	Ad hoc Referee:</p>
<p>
	Cell Death &amp; Disease, Cell Death and Differentiation, Frontiers in Cancer, Molecular and Cellular Oncology, Molecular Neurobiology, Oncogene, Oncotarget, Cell Cycle, FEBS Journal, Scientific Reports, Journal of Cellular Biochemestry, Molecular Oncology, FASEB Journal,&nbsp;Journal of Human Genetics, Biology Direct</p>
<p>
	<span class="totem_bold">RESEARCH INTEREST</span></p>
<p>
	MA is mainly interested in the characterization of transgenic mice with genetic alterations in the p53 family genes and their targets to understand their effect on development and cancer. In particular, he aims to investigate the role of the transcription factor ZNF750 (transcriptionally regulated by p63) in tumorogenesis by using combing&nbsp;in vitro&nbsp;and&nbsp;in vivomodels combined with system biology (transcriptomics, proteomics and metabolomics). Currently, MA is mainly involved on:</p>
<p>
	1) Dissecting&nbsp;in-vivo&nbsp;functions of specific p53-family gene isoforms in tumorigenesis.</p>
<p>
	2) Targeting lipid metabolism for cancer treatment</p>
<p>
	3) To identify&nbsp;in-vivo&nbsp;functions of ZNF750 in development, physiology and tumorigenesis by using genetically modified animals.</p>
<p>
	&nbsp;</p>
<p>
	&nbsp;</p>
<p>
	<span class="totem_bold">PUBLICATION</span></p>
<p class="totem_indent">
	Scientific Papers&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;86 (First Author: 20; Corresponding Author: 14)</p>
<p>
	Citations&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7886 (Scholar)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5285 (ISI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5694 (Scopus)</p>
<p>
	h-Index&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;46 (Scholar)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;38 (ISI)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;40 (Scopus)</p>
<p>
	<span class="totem_bold">Most representative publication&nbsp;</span></p>
<p>
	1)&nbsp;&nbsp;&nbsp;&nbsp;Zhu M, et al&nbsp;Agostini M&nbsp;Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype&nbsp;Discov Oncol.&nbsp;2024 Jan 16;15(1):10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p>
	2)&nbsp;&nbsp;&nbsp;&nbsp;Peng F, et al&nbsp;Alleviating hypoxia to improve cancer immunotherapy&nbsp;Oncogene&nbsp;2023 Dec;42(49):3591-3604</p>
<p>
	3)&nbsp;&nbsp;&nbsp;&nbsp;Butera A*,&nbsp;Agostini M*,&nbsp;et al ZFP750 affects the cutaneous barrier through regulating lipid metabolism&nbsp;Science Advances&nbsp;2023 Apr 28;9(17).&nbsp;(*) Co-First Author</p>
<p>
	4)&nbsp;&nbsp;&nbsp;&nbsp;Vitale I, et al. Apoptotic cell death in disease&mdash;Current understanding of the NCCD 2023&nbsp;Cell Death Differ&nbsp;2023 May;30(5):1097-1154</p>
<p>
	5)&nbsp;&nbsp;&nbsp;&nbsp;Agostini M*, et al&nbsp;Targeting lipid metabolism in cancer: neuroblastoma&nbsp;Cancer Metastasis&nbsp;Rev&nbsp;2022 Jun 10. doi: 10.1007/s10555-022-10040-8&nbsp;(*) Corresponding Author</p>
<p>
	6)&nbsp;&nbsp;&nbsp;&nbsp;Rugolo F, et al and&nbsp;Agostini M&nbsp;The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome&nbsp;Oncogene&nbsp;2021 Sep;40(38):5741-5751</p>
<p>
	7)&nbsp;&nbsp;&nbsp;&nbsp;Velletri T et al. Loss of p53 in mesenchymal stem cells promotes alteration of bone remodelling through negative regulation of osteoprotegerin.&nbsp;Cell Death Differ&nbsp;2020 Online ahead of print.</p>
<p>
	8)&nbsp;&nbsp;&nbsp;&nbsp;Amelio I et al&nbsp;The p73 C-terminus directs hippocampal development&nbsp;Proc Natl Acad Sci U S A2020&nbsp;117&nbsp;(27)&nbsp;15694-15701</p>
<p>
	9)&nbsp;&nbsp;&nbsp;&nbsp;Cassandri M et al.&nbsp;Agostini&nbsp;M&nbsp;and Melino G&nbsp;ZNF750 represses breast cancer invasion via epigenetic control of prometastatic genes&nbsp;Oncogene&nbsp;2020&nbsp;39,&nbsp;4331&ndash;4343&nbsp;</p>
<p>
	10)&nbsp;Agostini M, et al&nbsp;p73 regulates primary cortical neurons metabolism: a global metabolic profile&nbsp;Mol Neurobiol.&nbsp;2017&nbsp;2017 May 6. doi: 10.1007/s12035-017-0517-3.</p>
<p>
	11)&nbsp;Agostini M, et al&nbsp;Metabolic reprogramming during neuronal differentiation&nbsp;Cell Death Differ&nbsp;2016 Sep 1;23(9):1502-14.</p>
<p>
	12)&nbsp;Viticchi&egrave; G, et al&nbsp;ΔNp63&nbsp;supports aerobic respiration through hexokinase II&nbsp;Proc Natl Acad Sci USA. 2015 Sep 15;112(37):11577-82.&nbsp;</p>
<p>
	13)&nbsp;Amelio I, et al. Serine and glycine metabolism in Cancer&nbsp;Trends Biochem&nbsp;Sci&nbsp;2014 Apr;39(4):191-198.</p>
<p>
	14)&nbsp;Inoue S, et al. TAp73 is required for spermatogenesis and the maintenance of male fertility.&nbsp;Proc Natl Acad Sci USA. 2014;111(5):1843-8.&nbsp;</p>
<p>
	15)&nbsp;Niklison-Chirou MV, et al. TAp73 knockout mice show morphological and functional nervous system defects associated with loss of p75NTR&nbsp;&nbsp;Proc Natl Acad Sci U S A&nbsp;2013;110 (47):18952-7.&nbsp;</p>
<p>
	16)&nbsp;Tucci P*,&nbsp;Agostini M*, et al.&nbsp;Loss of p63 and its miR-205 target results in enhanced cell migration and metastasis in prostate cancer.&nbsp;Proc Natl Acad Sci U S A.&nbsp;2012 109(38):15312-7.&nbsp;(*) Co-First Author&nbsp;</p>
<p>
	17)&nbsp;He Z, et al.&nbsp;p73&nbsp;regulates autophagy and hepatocellular lipid metabolism through a transcriptional activation of the ATG5 gene.&nbsp;Cell Death Differ.&nbsp;2013 Oct;20(10):1415-24.</p>
<p>
	18)&nbsp;Amelio I, et al. p73 regulates serine biosynthesis in cancer.&nbsp;Oncogene.&nbsp;2013. doi: 10.1038/onc.2013.456.</p>
<p>
	19)&nbsp;Agostini M, et al. miR-34a regulates neurite outgrowth, spinal morphology and function.&nbsp;
	Proc Natl Acad Sci U S A.&nbsp;2011;108(52):21099-104.</p>
<p>
	20)&nbsp;Agostini M, et al.&nbsp;Neuronal differentiation by TAp73 is mediated by miR-34a regulation of synaptic protein targets.&nbsp;Proc Natl Acad Sci U S A. 2011;108(52):21093-8.</p></document> a:0:{}"
      }
      ["meta_keywords"]=>
      array(1) {
        [0]=>
        string(1) ","
      }
      ["reserved"]=>
      array(1) {
        [0]=>
        string(1) "0"
      }
      ["auth_ip"]=>
      array(1) {
        [0]=>
        string(1) "0"
      }
    }
    ["_fieldBoosts":protected]=>
    array(6) {
      ["content_id"]=>
      bool(false)
      ["content_title"]=>
      bool(false)
      ["description"]=>
      bool(false)
      ["meta_keywords"]=>
      bool(false)
      ["reserved"]=>
      bool(false)
      ["auth_ip"]=>
      bool(false)
    }
  }
}